Lineage Cell Therapeutics, Inc. - Common shares (LCTX)

Historical Holders from Q2 2019 to Q3 2025

Symbol
LCTX on NYSE
CUSIP
53566P109
Type / Class
Equity / Common shares
Shares outstanding
250M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
87.9M
Holdings value
$149M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
111
Number of buys
40
Number of sells
-66
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lineage Cell Therapeutics, Inc. - Common shares (LCTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BROADWOOD PARTNERS, L.P. 23.1% -5.6% $97.8M 57.8M 0% NEAL C. BRADSHER Nov 12, 2025
Chernett Jorey 5% $13.8M 11.4M Chernett Jorey Sep 22, 2025
BlackRock, Inc. 1% -80% $2.03M -$8.37M 2.23M -80.5% BlackRock, Inc. Jun 30, 2025

Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 87.9M $149M -$9.35M $1.69 111
2025 Q2 97.8M $88.4M -$8.83M $0.91 128
2025 Q1 109M $49.7M +$370K $0.45 126
2024 Q4 107M $53.8M +$3.92M $0.50 118
2024 Q3 94.6M $85.6M -$260K $0.91 113
2024 Q2 94.4M $94.2M +$447K $1.00 111
2024 Q1 93.4M $138M +$26.5M $1.48 113
2023 Q4 75.7M $82.5M +$189K $1.09 114
2023 Q3 75.5M $89.1M -$399K $1.18 103
2023 Q2 75.6M $107M +$8.46M $1.41 105
2023 Q1 69.8M $105M +$7.2M $1.50 115
2022 Q4 65.1M $76.1M +$592K $1.17 99
2022 Q3 64.7M $73.1M -$348K $1.13 89
2022 Q2 65M $103M -$12.1M $1.58 85
2022 Q1 72.8M $112M -$3.92M $1.54 100
2021 Q4 74M $181M -$5.35M $2.45 111
2021 Q3 75.8M $192M +$6.65M $2.52 106
2021 Q2 73.1M $209M +$38M $2.85 101
2021 Q1 60.3M $142M +$12.4M $2.35 88
2020 Q4 55.1M $96.9M +$3.14M $1.76 77
2020 Q3 53.6M $50.2M -$1.85M $0.94 65
2020 Q2 55.7M $48.5M -$6.97M $0.87 80
2020 Q1 63.8M $52.9M +$406K $0.83 80
2019 Q4 63.3M $56.4M -$1.15M $0.89 85
2019 Q3 64.5M $63.2M +$63M $0.98 80
2019 Q2 18K $20K +$20K $1.11 1